Association of genetic polymorphisms in the paraoxonase 1 gene with the risk and prognosis of non-small cell lung cancer in Chinese han population

Journal of Investigative Medicine

Volumn 60, Issue 3, 2012, Pages 592-597

  Wang, Hui ^a   Li, Lin ^a   Ding, Li ^a   Zhang, Zijin ^a   Pu, Chun ^a  

^a BEIJING HOSPITAL   (China)

Author keywords

Non small cell lung cancer; Paraoxonase; Polymorphism; Prognosis; Risk

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DNA POLYMORPHISM; FAMILY HISTORY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; ARYLDIALKYLPHOSPHATASE; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS;

EID: 84860815998     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318245d557     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CACancer J Clin. 2010;60:277-300.
2. Farinati F, Piciocchi M, Lavezzo E, et al. Oxidative stress and inducible nitric oxide synthase induction in carcinogenesis. Dig Dis. 2010;28:579-584.
3. Antognelli C, Del Buono C, Ludovini V, et al. CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: An Italian case-control study. BMC Cancer. 2009;9:115.
4. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-287. (Pubitemid 28335041)
5. Ak0ay MN, Yilmaz I, Polat MF, et al. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology. 2003;50:cclxxiiiYcclxxv.
6. Ak0ay MN, Polat MF, Yilmaz I, et al. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology. 2003;50:ccxxvYccxxvii.
7. Camuzcuoglu H, Arioz DT, Toy H, et al. Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer. Gynecol Oncol. 2009;112:481-485.
8. Arioz DT, Camuzcuoglu H, Toy H, et al. Assessment of serum paraoxonase and arylesterase activity in patients with endometrial cancer. Eur J Gynaecol Oncol. 2009;30:679-682.
9. Elkiran ET, Mar N, Aygen B, et al. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer. 2007;7:48.
10. Adkins S, Gan KN, Mody M, et al. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993;52:598-608. (Pubitemid 23311330)
11. Leviev I, Deakin S, James RW. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res. 2001;42:528-535. (Pubitemid 32366995)
12. Brophy VH, Jampsa RL, Clendenning JB, et al. Effects of 5 regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet. 2001;68:1428-1436. (Pubitemid 32510618)
13. Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 2000;101:2510-2517. (Pubitemid 30366256)
14. Hussein YM, Gharib AF, Etewa RL, et al. Association of L55M and Q192R polymorphisms in paraoxonase 1 (PON1) gene with breast cancer risk and their clinical significance. Mol Cell Biochem. 2011;351:117-123.
15. Lurie G, Wilkens LR, Thompson PJ, et al Genetic polymorphisms in the Paraoxonase 1 gene and risk of ovarian epithelial carcinoma. Cancer Epidemiol Biomarkers Prev. 2008;17:2070-2077.
16. Antognelli C, Mearini L, Talesa VN, et al. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate. 2005;63:240-251. (Pubitemid 40571058)
17. Humbert R, Adler DA, Disteche CM, et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993;3:73-76. (Pubitemid 23063292)
18. Zama T, Murata M, Matsubara Y, et al. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol. 1997;17:3565-3569. (Pubitemid 28028569)
19. DurackováZ. Some current insights into oxidative stress. Physiol Res. 2010;59:459-469.
20. Klaunig JE, Kamendulis LM, Hocevar BA. Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol. 2010;38:96-109.
21. Fang J, Seki T, Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev. 2009;61: 290-302.
22. Visconti R, Grieco D. New insights on oxidative stress in cancer. Curr Opin Drug Discov Dev. 2009;12:240-245.
23. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581-1590. (Pubitemid 28198486)
24. Lee CH, Lee KY, Choe KH, et al. Effects of oxidative DNA damage induced by polycyclic aromatic hydrocarbons and genetic polymorphism of the paraoxonase-1 (PON1) gene on lung cancer. J Prev Med Public Health. 2005;38:345-350.
25. Aksoy-Sagirli P, Cakmakoglu B, Isbir T, et al. Paraoxonase-1 192/55 polymorphisms and the risk of lung cancer in a Turkish population. Anticancer Res. 2011;31:2225-2229.
26. Van Der Logt EM, Janssen CH, Van Hooijdonk Z, et al. No association between genetic polymorphisms in NAD(P)H oxidase p22phox and paraoxonase 1 and colorectal cancer risk. Anticancer Res. 2005;25:1465-1470. (Pubitemid 40546830)
27. Martínez C, Molina JA, Alonso-Navarro H, et al. Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma. BMC Neurol. 2010;10:71.
28. Hu Z, Wu C, Shi Y, et al. A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet. 2011;43:792-796.
29. Naidu R, Har YC, Taib NA. Genetic polymorphisms of paraoxonase 1 (PON1) gene: Association between L55M or Q192R with breast cancer risk and clinico-pathological parameters. Pathol Oncol Res. 2010, in press.
30. Rosell R, Taron M, Massuti B, et al. Predicting response to chemotherapy with early-stage lung cancer. Cancer J. 2011;17:49-56.
31. Pirker R, Minar W. Chemotherapy of advanced nonYsmall cell lung cancer. Front Radiat Ther Oncol. 2010;42:157-163.
32. Pfister DG, Ridge JA. Induction chemotherapy for larynx preservation: Patient selection or therapeutic effect? J Clin Oncol. 2006;24:540-543. (Pubitemid 46630414)